Importantly, we also found that the response to PRMT5 inhibition did not correlate with the ratio of expression of CLNS1A to RIOK1 (Supplementary Fig. 2d), which was previously reported as a biomarker of sensitivity to PRMT5 inhibition in a panel of immortalized glioma cell lines34. The gene discussed is RIOK1; the disease is central nervous system cancer.